Reading Time: 5 minutes Hi everyone! My name’s Katie and I recently joined the Association as a Supporter Information Officer. My role offers me a unique perspective as I
Category: Treatments
Reading Time: 5 minutes The MND clinical trial landscape has grown vastly over the last decade and this has led to increased opportunities for people with MND to take
Reading Time: 6 minutes MND is a very complex disease, and in the UK there is still only one approved treatment so the need for more effective treatments remains
Reading Time: 5 minutes The current pace of clinical trials means that there are now more trials testing potential drugs for MND in the UK than ever before. One
Reading Time: 6 minutes MND is a complex disease, and the causes are still not fully understood. Researchers all around the world are working tirelessly on different theories to
Reading Time: 5 minutes The pace of MND research continues to increase, with more clinical trials underway in the UK, over the last year, than ever before. Adding to this momentum, the clinical platform trial MAGNET (Multi-arm, Adaptive, Group-sequential trial NETwork)has just opened to recruitment in the UK.
Over the last several decades, there have been over 140 clinical trials for MND and unfortunately most of these have not led to effective treatments. More recently, clinical trial design has become more innovative, including the use of platform trials. MAGNET is a platform trial which aims to accelerate the development of new potential treatments for MND by testing multiple drugs simultaneously.
Reading Time: 5 minutes Recent research, led by scientists at the University of Edinburgh and University of Dundee, has identified abnormalities in a type of brain cell called microglia
Reading Time: 4 minutes A new clinical trial, investigating Dazucorilant, for the treatment of MND is now open for recruitment in the UK. With this trial, there are now
Reading Time: 7 minutes On 25th April 2023 Tofersen (now known as Qalsody in the US), a treatment for SOD1 MND was approved by the Food and Drug Administration
Reading Time: 6 minutes Recent research, led by Professor Guillaume Hautbergue at the University of Sheffield, has found a potential new method of preventing nerve cell death in the